DK1991258T3 - Kollagenase til behandling af cellulite - Google Patents

Kollagenase til behandling af cellulite Download PDF

Info

Publication number
DK1991258T3
DK1991258T3 DK07751508.8T DK07751508T DK1991258T3 DK 1991258 T3 DK1991258 T3 DK 1991258T3 DK 07751508 T DK07751508 T DK 07751508T DK 1991258 T3 DK1991258 T3 DK 1991258T3
Authority
DK
Denmark
Prior art keywords
collagenase
cellulite
purified
treatment
use according
Prior art date
Application number
DK07751508.8T
Other languages
English (en)
Inventor
Marie A Badalemente
Alexander B Dagum
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Application granted granted Critical
Publication of DK1991258T3 publication Critical patent/DK1991258T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Claims (7)

1. Renset kollagenase for anvendelse ved behandling af cellulite i en menneskelig patient ved at give det til det kollagene septumnetvserk, hvori kollagenasen er i det vsesentlige fri for andre enzymer, hvori den rensede kollagenase indsprojtes i en dosis omfattende mindst 10.000 ABC-enheder givet i en eller flere indsprojt-ninger, og hvori kollagenasen renses for bakterien Clostridium histolyticum.
2. Renset kollagenase til anvendelse ifolge krav 1, hvori den rensede kollagenase gives i fravser af triamcinolon eller andre kortikosteroider.
3. Renset kollagenase til anvendelse ifolge krav 1, hvori den rensede kollagenase indsprojtes i et volumen pá 1,0 mi.
4. Renset kollagenase til anvendelse ifolge krav 1, hvori den rensede kollagenase indsprojtes flere steder.
5. Renset kollagenase til anvendelse ifolge krav 1, hvori den rensede kollagenase bestár af kollagenase I og kollagenase II.
6. Renset kollagenase til anvendelse ifolge krav 1, hvori behandlingen gentages efter omkring fire til seks uger.
7. Renset kollagenase til anvendelse ifolge krav 5, hvori den rensede kollagenase gives i en farmaceutisk acceptabel vseskeformet bserer og omfatter kollagenase I og kollagenase II i et masseforhold pá 1 til 1.
DK07751508.8T 2006-02-22 2007-02-22 Kollagenase til behandling af cellulite DK1991258T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77569006P 2006-02-22 2006-02-22
US11/703,269 US20070224184A1 (en) 2006-02-22 2007-02-07 Method for treating cellulite
PCT/US2007/004752 WO2007100675A2 (en) 2006-02-22 2007-02-22 Collagenase for treating cellulite

Publications (1)

Publication Number Publication Date
DK1991258T3 true DK1991258T3 (da) 2015-11-16

Family

ID=38325147

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07751508.8T DK1991258T3 (da) 2006-02-22 2007-02-22 Kollagenase til behandling af cellulite

Country Status (19)

Country Link
US (4) US20070224184A1 (da)
EP (1) EP1991258B1 (da)
JP (5) JP5775658B2 (da)
KR (2) KR20080108996A (da)
AU (1) AU2007221225B2 (da)
BR (1) BRPI0708186A2 (da)
CA (1) CA2643171C (da)
DK (1) DK1991258T3 (da)
ES (1) ES2553184T3 (da)
HR (1) HRP20151182T1 (da)
HU (1) HUE025918T2 (da)
IL (1) IL193639A (da)
MX (1) MX2008010767A (da)
NZ (1) NZ570642A (da)
PL (1) PL1991258T3 (da)
PT (1) PT1991258E (da)
RS (1) RS54372B1 (da)
SI (1) SI1991258T1 (da)
WO (1) WO2007100675A2 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958150B2 (en) 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
MX2007008764A (es) * 2005-01-21 2007-10-19 Advance Biofactures Corp Metodos para tratar capsulitis adhesiva.
US20090233885A1 (en) * 2006-07-14 2009-09-17 Duncan Diane I Compositions and Methods for Fat Reduction
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
US20110229451A2 (en) * 2009-03-06 2011-09-22 Halozyme, Inc. Temperature sensitive mutants of matrix metalloproteases and uses thereof
JP5284239B2 (ja) * 2009-10-07 2013-09-11 株式会社メタコ スクリーン装置
FR2966734B1 (fr) 2010-10-29 2014-07-18 Max Rombi Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides
FI3581199T3 (fi) * 2011-10-21 2023-08-18 Endo Global Ventures Menetelmiä turvottavan fibroskleroottisen pannikulopatian hoitamiseksi tai vähentämiseksi
ES2968836T3 (es) 2012-01-12 2024-05-14 Endo Global Ventures Enzima del clostridium histolyticum
WO2014066622A2 (en) 2012-10-24 2014-05-01 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
US20150196625A9 (en) 2013-01-07 2015-07-16 Rudolph D. Paladini Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof
US9744138B2 (en) 2013-03-15 2017-08-29 Biospecifics Technologies Corp. Treatment method and product for uterine fibroids using purified collagenase
US10117892B2 (en) 2013-08-29 2018-11-06 Allergan, Inc. Devices and methods for reducing the appearance of cellulite
CN103751102A (zh) 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
IL301796A (en) * 2017-03-01 2023-05-01 Endo Ventures Ltd A method for evaluating and treating cellulite
WO2018183582A2 (en) 2017-03-28 2018-10-04 Endo Ventures Limited Improved method of producing collagenase
WO2020021332A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020021330A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
CN113015514A (zh) * 2018-09-18 2021-06-22 恩多全球美学有限公司 用于治疗皮下脂肪团的组合物和方法
KR20210113271A (ko) * 2019-01-06 2021-09-15 엔도 글로벌 에스테틱스 리미티드 콜라게나제 제형 및 이의 제조 방법
EP4045078A1 (en) 2019-10-15 2022-08-24 The Johns Hopkins University Treatment of uterine fibroids using purified collagenase
EP4041288A4 (en) * 2019-11-26 2023-02-22 Standard of Care Corporation HYALURONIDASE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING CELLULITE
WO2023218384A1 (en) * 2022-05-10 2023-11-16 Endo Global Aesthetics Limited Methods of reducing collagenase-mediated bruising in a subject having cellulite

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338300A (en) * 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4645668A (en) * 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US5393792A (en) * 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5332503A (en) * 1993-04-16 1994-07-26 Baxter International Inc. Process for purifying collagenase
WO1996000283A1 (en) * 1994-06-24 1996-01-04 Boehringer Mannheim Corporation A purified mixture of collagenases and two other proteases obtained from clostridium histolyticum
US5589171A (en) * 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
CA2158822C (en) * 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
US6958150B2 (en) * 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US5830741A (en) * 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
US6086872A (en) * 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
AU738512B2 (en) * 1997-10-03 2001-09-20 Lavipharm Laboratories, Inc. A prolamine-plant polar lipid composition, its method of preparation and applications thereof
US6022539A (en) * 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
WO2001013865A1 (en) * 1999-08-20 2001-03-01 Howard Murad Pharmaceutical compositions and methods for reducing the appearance of cellulite
MX2007008764A (es) * 2005-01-21 2007-10-19 Advance Biofactures Corp Metodos para tratar capsulitis adhesiva.
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases

Also Published As

Publication number Publication date
AU2007221225A1 (en) 2007-09-07
WO2007100675A2 (en) 2007-09-07
US20220249348A1 (en) 2022-08-11
JP6649449B2 (ja) 2020-02-19
JP6498167B2 (ja) 2019-04-10
JP2015134840A (ja) 2015-07-27
IL193639A (en) 2015-01-29
PT1991258E (pt) 2015-11-24
MX2008010767A (es) 2008-09-01
PL1991258T3 (pl) 2016-04-29
WO2007100675A3 (en) 2007-11-15
CA2643171A1 (en) 2007-09-07
BRPI0708186A2 (pt) 2011-05-24
US10123959B2 (en) 2018-11-13
US20190053995A1 (en) 2019-02-21
JP2018199733A (ja) 2018-12-20
JP6853331B2 (ja) 2021-03-31
JP2009527570A (ja) 2009-07-30
US20160279046A1 (en) 2016-09-29
HRP20151182T1 (hr) 2016-01-01
ES2553184T3 (es) 2015-12-04
US20070224184A1 (en) 2007-09-27
JP2020015771A (ja) 2020-01-30
CA2643171C (en) 2018-10-02
NZ570642A (en) 2012-03-30
EP1991258B1 (en) 2015-08-12
IL193639A0 (en) 2011-08-01
AU2007221225B2 (en) 2010-02-11
JP5775658B2 (ja) 2015-09-09
HUE025918T2 (en) 2016-05-30
KR20080108996A (ko) 2008-12-16
KR20120006063A (ko) 2012-01-17
EP1991258A2 (en) 2008-11-19
JP2016204396A (ja) 2016-12-08
SI1991258T1 (sl) 2016-02-29
RS54372B1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
DK1991258T3 (da) Kollagenase til behandling af cellulite
JP6955491B2 (ja) 治療効果又は美容効果の長い持続時間を有する、注射用ボツリヌス毒素製剤及びこれらの使用方法
US20090010918A1 (en) Methods for treatment using collagenase
US9480732B2 (en) Methods for treatment of incontinence associated with sexual activity
AU2018258591A1 (en) Botulinum neurotoxins production methods
WO2007100590A2 (en) Methods for treating cellulite
WO2013050959A1 (en) Composition for the treatment of skin lesions
JP2024023429A (ja) 皮膚状態の処置のための組成物
US9636385B2 (en) Use of collagenase to treat glaucoma
EP3556342A1 (en) Cosmetic multilevel method for cellulite and/or skin flaccidity